GSA Capital Partners LLP Invests $740,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

GSA Capital Partners LLP acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 22,493 shares of the company’s stock, valued at approximately $740,000. GSA Capital Partners LLP owned about 0.06% of Tarsus Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. bought a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at about $28,904,000. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in Tarsus Pharmaceuticals by 1,113.5% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 898,000 shares of the company’s stock valued at $32,642,000 after purchasing an additional 824,000 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Tarsus Pharmaceuticals in the first quarter valued at approximately $12,640,000. Millennium Management LLC raised its holdings in Tarsus Pharmaceuticals by 1,259.3% in the second quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock worth $9,475,000 after purchasing an additional 322,942 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Tarsus Pharmaceuticals by 14.5% during the first quarter. Vanguard Group Inc. now owns 1,826,632 shares of the company’s stock worth $66,398,000 after purchasing an additional 231,131 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. The Goldman Sachs Group raised their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday. Finally, Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Stock Down 3.9 %

NASDAQ:TARS opened at $44.83 on Monday. The stock has a 50-day simple moving average of $37.84 and a 200 day simple moving average of $32.53. Tarsus Pharmaceuticals, Inc. has a 52-week low of $15.60 and a 52-week high of $52.99. The company has a market cap of $1.71 billion, a PE ratio of -11.77 and a beta of 1.00. The company has a debt-to-equity ratio of 0.30, a quick ratio of 6.99 and a current ratio of 5.42.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.